Citations

Mayo Clinic

Clear

955 citation(s) found for "Fu, Ashley".

Detrimental Effects of Tumor Progression on Cognitive Function of Patients With High-Grade Glioma
Brown, Paul D. , Jensen, Ashley W., Felten, Sara J., Schaefer, Paul, Jaeckle, Kurt A. , Cerhan, Jane H. , Buckner, Jan C. , Ballman, Karla V.

Journal of Clinical Oncology | November 30, 2006 | Volume: 24 | Issue: 34 | Pages: 5427-5433

10.1200/jco.2006.08.5605 | PMID 17135644 Get It

Purpose There is growing recognition that the primary cause of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more significantly, tumor progression. To assess the cognitive performance of high-grade glioma patients, prospectively collected cognitive performance data were analyzed. Patients and Methods We studied 1,244 high-grade brain tumor patients entered onto eight consecutive North Central Cancer Treatment Group treatment trials that used radiation and nitrosourea-based chemotherapy. Imaging studies and Folstein Mini-Mental State Examination (MMSE) scores recorded at baseline, 6, 12, 18, and 24 months were analyzed to assess tumor status and cognitive function over time. Results The proportion of patients without tumor progression who experienced clinically significant cognitive deterioration compared with baseline was stable at 6, 12, 18, and 24 months (18%, 16%, 14%, and 13%, respectively). In patients without radiographic evidence of progression, clinically significant deterioration in MMSE scores was a strong predictor of a more rapid time to tumor progression and death. At evaluations preceding interval radiographic evidence of progression, there was significant deterioration in MMSE scores for patients who were to experience progression, whereas the scores remained stable for the patients who did not have tumor progression. Conclusion The proportion of high-grade glioma patients with cognitive deterioration over time is stable, most consistent with the constant pressure of tumor progression over time. Although other factors may contribute to cognitive decline, the predominant cause of cognitive decline seems to be subclinical tumor progression that precedes radiographic changes.
P3–163: Identification of a novel risk gene for progressive supranuclear palsy by a genome–wide scan of 500,288 SNPs
Melquist, Stacey , Huentelman, Matthew J. , Craig, David W. , Baker, Matt , Zisman, Victoria L., Gass, Jennifer , Adamson, Jennifer, Szelinger, Szabolcs , Cournevaux, Jason J., Coon, Keith D., Stephan, Dietrich A. , Hutton, Michael , Crook, Richard , Pearson, John V. , Cannon, Ashley , Dickson, Dennis W.

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_14 | Pages: No page available

10.1016/j.jalz.2006.05.1431 Get It

A cost analysis of a tele-oncology practice in the United States
Doolittle, Gary C. , Williams, Arthur R., Spaulding, Ashley, Spaulding, Ryan , Cook, David J.

Journal of Telemedicine and Telecare | December 4, 2004 | Volume: 10 | Issue: 1_suppl | Pages: 27-29

10.1258/1357633042614429 | PMID 15603601 Get It

Oncology services have been provided by telemedicine from the University of Kansas Medical Center (KUMC) for almost 10 years. We have analysed the costs associated with providing tele-oncology clinics to a rural Kansas town for two fiscal years, 1995 and 2000. The aim was to compare recent tele-oncology costs with those of the first year of tele-oncology practice. A study conducted in 1995 showed that the average cost was $812 per telemedicine consultation. Data from fiscal year 2000 showed that the average cost was $410 per telemedicine consultation, a decrease of almost 50%. As the tele-oncology practice in Kansas continues to grow, it can be expected that the costs associated with providing tele-oncology services will continue to decline.
CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal Tract
Brenchley, Jason M. , Schacker, Timothy W. , Ruff, Laura E., Price, David A. , Taylor, Jodie H., Beilman, Gregory J. , Nguyen, Phuong L., Khoruts, Alexander , Larson, Matthew , Haase, Ashley T. , Douek, Daniel C.

The Journal of Experimental Medicine | September 13, 2004 | Volume: 200 | Issue: 6 | Pages: 749-759

10.1084/jem.20040874 | PMID 15365096 Get It

The mechanisms underlying CD4+ T cell depletion in human immunodeficiency virus (HIV) infection are not well understood. Comparative studies of lymphoid tissues, where the vast majority of T cells reside, and peripheral blood can potentially illuminate the pathogenesis of HIV-associated disease. Here, we studied the effect of HIV infection on the activation and depletion of defined subsets of CD4+ and CD8+ T cells in the blood, gastrointestinal (GI) tract, and lymph node (LN). We also measured HIV-specific T cell frequencies in LNs and blood, and LN collagen deposition to define architectural changes associated with chronic inflammation. The major findings to emerge are the following: the GI tract has the most substantial CD4+ T cell depletion at all stages of HIV disease; this depletion occurs preferentially within CCR5+ CD4+ T cells; HIV-associated immune activation results in abnormal accumulation of effector-type T cells within LNs; HIV-specific T cells in LNs do not account for all effector T cells; and T cell activation in LNs is associated with abnormal collagen deposition. Taken together, these findings define the nature and extent of CD4+ T cell depletion in lymphoid tissue and point to mechanisms of profound depletion of specific T cell subsets related to elimination of CCR5+ CD4+ T cell targets and disruption of T cell homeostasis that accompanies chronic immune activation.
Nonhuman primate parthenogenetic stem cells
Vrana, Kent E. , Hipp, Jason, Goss, Ashley , McCool, Brian A. , Riddle, David R., Wettstein, Peter J., Studer, Lorenz , Tabar, Viviane , Cunniff, Kerrianne, Chapman, Karen , Vilner, Lucy, West, Michael D. , Cibelli, José B. , Walker, Stephen J. , Grant, Kathleen A.

Proceedings of the National Academy of Sciences | September 30, 2003 | Volume: 100 | Issue: suppl_1 | Pages: 11911-11916

10.1073/pnas.2034195100 | PMID 14504386 Get It

Parthenogenesis is the biological phenomenon by which embryonic development is initiated without male contribution. Whereas parthenogenesis is a common mode of reproduction in lower organisms, the mammalian parthenote fails to produce a successful pregnancy. We herein describe in vitro parthenogenetic development of monkey ( Macaca fascicularis ) eggs to the blastocyst stage, and their use to create a pluripotent line of stem cells. These monkey stem cells (Cyno-1 cells) are positive for telomerase activity and are immunoreactive for alkaline phosphatase, octamer-binding transcription factor 4 (Oct-4), stage-specific embryonic antigen 4 (SSEA-4), tumor rejection antigen 1-60 (TRA 1-60), and tumor rejection antigen 1-81 (TRA 1-81) (traditional markers of human embryonic stem cells). They have a normal chromosome karyotype (40 + 2) and can be maintained in vitro in an undifferentiated state for extended periods of time. Cyno-1 cells can be differentiated in vitro into dopaminergic and serotonergic neurons, contractile cardiomyocyte-like cells, smooth muscle, ciliated epithelia, and adipocytes. When Cyno-1 cells were injected into severe combined immunodeficient mice, teratomas with derivatives from all three embryonic germ layers were obtained. When grown on fibronectin/laminin-coated plates and in neural progenitor medium, Cyno-1 cells assume a neural precursor phenotype (immunoreactive for nestin). However, these cells remain proliferative and express no functional ion channels. When transferred to differentiation conditions, the nestin-positive precursors assume neuronal and epithelial morphologies. Over time, these cells acquire electrophysiological characteristics of functional neurons (appearance of tetrodotoxin-sensitive, voltage-dependent sodium channels). These results suggest that stem cells derived from the parthenogenetically activated nonhuman primate egg provide a potential source for autologous cell therapy in the female and bypass the need for creating a competent embryo.